基于电动车的液体活检市场－全球产业规模、份额、趋势、机会和预测，按产品、工作流程、技术、样本类型、最终用户、地区和竞争格局细分，2020-2030 年预测

2024年全球以细胞外囊泡（EV）为基础的液体活检市场规模为9,112万美元，预计到2030年将以9.74%的复合年增长率增长至1.5914亿美元。基于细胞外囊泡的液体活检技术是对包裹在细胞外囊泡（例如外泌体）内的疾病特异性生物标记进行非侵入性分析，这些囊泡存在于血液或尿液等体液中。这些囊泡携带包括蛋白质、核酸和脂质在内的分子物质，能够提供有关来源细胞生理和病理状态的资讯。慢性疾病（尤其是癌症）在全球日益加重，以及对早期、非侵入性诊断解决方案的需求不断增长，是推动该市场扩张的主要因素。此外，EV在生物体液中固有的稳定性和丰富性，使其优于其他循环生物标记物，也是促进市场成长的关键因素。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球基于电动车的液体切片市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过提供（试剂盒和检测、服务、仪器）
  • 依工作流程（样品製备、定序、数据分析）
  • 依技术分类（隔离技术、分析技术）
  • 依样本类型（血液、尿液、唾液、其他）
  • 按最终用户（学术和研究机构、製药和生物技术公司、临床实验室）划分
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美电动车液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲电动车液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区以电动车为基础的液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲基于电动车的液体活检市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲电动车液体切片市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球以电动车为基础的液体切片市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Horiba Ltd.
• Thermo Fisher Scientific, Inc.
• Lonza Group AG
• Takara Bio Inc.
• Abcam plc
• Qiagen NV
• Malvern Panalytical Ltd.
• Revvity, Inc. (PerkinElmer, Inc)
• Norgen Biotek Corp.
• Bio-Techne Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global EV-Based Liquid Biopsy Market , valued at USD 91.12 Million in 2024, is projected to experience a CAGR of 9.74% to reach USD 159.14 Million by 2030. Extracellular vesicle (EV)-based liquid biopsy involves the non-invasive analysis of disease-specific biomarkers encapsulated within extracellular vesicles, such as exosomes, circulating in bodily fluids like blood or urine. These vesicles carry molecular cargoes including proteins, nucleic acids, and lipids, providing insights into the physiological and pathological state of originating cells. The market's expansion is significantly driven by the increasing global burden of chronic diseases, particularly cancer, and the rising demand for early, non-invasive diagnostic solutions. The inherent stability and abundance of EVs in biofluids, offering advantages over other circulating biomarkers, also act as key growth facilitators.

Key Market Drivers

The escalating global cancer burden fundamentally drives the EV-based liquid biopsy market. Traditional diagnostic methods often face limitations in early detection and continuous monitoring, areas where the non-invasive nature of EV liquid biopsies offers significant advantages. As cancer incidence continues its upward trajectory, the urgency for advanced, accessible diagnostic tools intensifies. According to the International Agency for Research on Cancer (IARC), in 2022, there were close to 20 million new cases of cancer worldwide. This pervasive health crisis necessitates innovative solutions that can accurately identify malignancies at earlier stages and monitor treatment efficacy without the invasiveness of tissue biopsies, directly propelling the adoption and development of EV-based platforms.

Key Market Challenges

A substantial challenge impeding the growth of the Global EV-Based Liquid Biopsy Market is the ongoing technical complexity associated with isolating and comprehensively characterizing extracellular vesicles (EVs) from complex biofluids. This inherent variability in isolation methods and subsequent characterization protocols often leads to significant issues with reproducibility and consistent clinical validation. The lack of standardized procedures across different laboratories and platforms directly compromises the reliability of test results, creating skepticism among clinicians and delaying the widespread adoption of EV-based diagnostic solutions.

Key Market Trends

The emergence of novel EV biomarkers is significantly shaping the global EV-based liquid biopsy market by enhancing diagnostic precision and expanding application areas. Research into disease-specific cargo within extracellular vesicles, such as proteins and nucleic acids, is uncovering new targets for early detection and disease monitoring across various pathologies. This focus on biomarker discovery drives the development of more sensitive and specific diagnostic assays. According to the International Society for Extracellular Vesicles, its MISEV2023 guidelines, published in March 2024, garnered consensus from approximately 97% of surveyed members, reflecting a widespread scientific commitment to standardizing and advancing EV research which underpins biomarker identification. This collective effort is crucial for translating promising biomarker candidates into validated clinical tools. Furthermore, a review article in *Biology (Basel)* in September 2024, highlighted the therapeutic opportunity of tumor-derived extracellular vesicles, emphasizing their capacity to harbor cancer-derived cargo reflective of their cell-of-origin and their superior stability in blood for diagnostic and prognostic insights.

Key Market Players

• Horiba Ltd.
• Thermo Fisher Scientific, Inc.
• Lonza Group AG
• Takara Bio Inc.
• Abcam plc
• Qiagen N.V.
• Malvern Panalytical Ltd.
• Revvity, Inc. (PerkinElmer, Inc)
• Norgen Biotek Corp.
• Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

EV-Based Liquid Biopsy Market , By Offering:

• Kits & Assays
• Services
• Instruments

EV-Based Liquid Biopsy Market , By Workflow:

• Sample Preparation
• Sequencing
• Data Analysis

EV-Based Liquid Biopsy Market , By Technology:

• Isolation Technologies
• Analysis Technologies

EV-Based Liquid Biopsy Market , By Sample Type:

• Blood
• Urine
• Saliva
• Others

EV-Based Liquid Biopsy Market , By End User:

• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Clinical Laboratories

EV-Based Liquid Biopsy Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global EV-Based Liquid Biopsy Market .

Available Customizations:

Global EV-Based Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global EV-Based Liquid Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offering (Kits & Assays, Services, Instruments)
  • 5.2.2. By Workflow (Sample Preparation, Sequencing, Data Analysis)
  • 5.2.3. By Technology (Isolation Technologies, Analysis Technologies)
  • 5.2.4. By Sample Type (Blood, Urine, Saliva, Others)
  • 5.2.5. By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America EV-Based Liquid Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offering
  • 6.2.2. By Workflow
  • 6.2.3. By Technology
  • 6.2.4. By Sample Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States EV-Based Liquid Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offering
      • 6.3.1.2.2. By Workflow
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Sample Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada EV-Based Liquid Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offering
      • 6.3.2.2.2. By Workflow
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Sample Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico EV-Based Liquid Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offering
      • 6.3.3.2.2. By Workflow
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Sample Type
      • 6.3.3.2.5. By End User

7. Europe EV-Based Liquid Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offering
  • 7.2.2. By Workflow
  • 7.2.3. By Technology
  • 7.2.4. By Sample Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany EV-Based Liquid Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offering
      • 7.3.1.2.2. By Workflow
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Sample Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France EV-Based Liquid Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offering
      • 7.3.2.2.2. By Workflow
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Sample Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom EV-Based Liquid Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offering
      • 7.3.3.2.2. By Workflow
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Sample Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy EV-Based Liquid Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offering
      • 7.3.4.2.2. By Workflow
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Sample Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain EV-Based Liquid Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offering
      • 7.3.5.2.2. By Workflow
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Sample Type
      • 7.3.5.2.5. By End User

8. Asia Pacific EV-Based Liquid Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offering
  • 8.2.2. By Workflow
  • 8.2.3. By Technology
  • 8.2.4. By Sample Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China EV-Based Liquid Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offering
      • 8.3.1.2.2. By Workflow
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Sample Type
      • 8.3.1.2.5. By End User
  • 8.3.2. India EV-Based Liquid Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offering
      • 8.3.2.2.2. By Workflow
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Sample Type
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan EV-Based Liquid Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offering
      • 8.3.3.2.2. By Workflow
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Sample Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea EV-Based Liquid Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offering
      • 8.3.4.2.2. By Workflow
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Sample Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia EV-Based Liquid Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offering
      • 8.3.5.2.2. By Workflow
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Sample Type
      • 8.3.5.2.5. By End User

9. Middle East & Africa EV-Based Liquid Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offering
  • 9.2.2. By Workflow
  • 9.2.3. By Technology
  • 9.2.4. By Sample Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia EV-Based Liquid Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offering
      • 9.3.1.2.2. By Workflow
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Sample Type
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE EV-Based Liquid Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offering
      • 9.3.2.2.2. By Workflow
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Sample Type
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa EV-Based Liquid Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offering
      • 9.3.3.2.2. By Workflow
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Sample Type
      • 9.3.3.2.5. By End User

10. South America EV-Based Liquid Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offering
  • 10.2.2. By Workflow
  • 10.2.3. By Technology
  • 10.2.4. By Sample Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil EV-Based Liquid Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offering
      • 10.3.1.2.2. By Workflow
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Sample Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia EV-Based Liquid Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offering
      • 10.3.2.2.2. By Workflow
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Sample Type
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina EV-Based Liquid Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offering
      • 10.3.3.2.2. By Workflow
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Sample Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global EV-Based Liquid Biopsy Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Horiba Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific, Inc.
• 15.3. Lonza Group AG
• 15.4. Takara Bio Inc.
• 15.5. Abcam plc
• 15.6. Qiagen N.V.
• 15.7. Malvern Panalytical Ltd.
• 15.8. Revvity, Inc. (PerkinElmer, Inc)
• 15.9. Norgen Biotek Corp.
• 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer